UPDATE 1-FDA expands use of Imbruvica to treat rare form of blood cancer

Jan 29 (Reuters) - The U.S. Food and Drug Administration said it cleared an expanded use of Imbruvica to treat Waldenström's macroglobulinemia (WM), a rare form of blood cancer for which no specific pharmaceutical therapy exists.